Read More Pharma Industry News Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more. bySoujanya RaviMay 24, 2026